# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 29, 2025

# SYNOPSYS, INC.

(Exact name of registrant as specified in charter)

Delaware (State or other jurisdiction of incorporation) 000-19807 (Commission File Number) 56-1546236 (I.R.S. Employer Identification No.)

675 Almanor Ave. Sunnyvale, California 94085 (Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: (650) 584-5000

N/A

(Former name or former address, if changed since last report)

	appropriate box below if the Form 8-K filing is interprovisions:	nded to simultaneously satisfy the filir	ng obligation of the registrant under any of the		
	Written communications pursuant to Rule 425 u	under the Securities Act (17 CFR 230.4)	25)		
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))				
Securities 1	registered pursuant to Section 12(b) of the Act:				
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered		
Commo	on Stock (par value of \$0.01 per share)				
Indicate by		Symbol(s) SNPS growth company as defined in Rule 40	on which registered  Nasdaq Global Select Market		
Indicate by	on Stock (par value of \$0.01 per share)  y check mark whether the registrant is an emerging	Symbol(s) SNPS growth company as defined in Rule 40	on which registered  Nasdaq Global Select Market		

#### Item 7.01 Regulation FD Disclosure.

In connection with BIS Letter (as discussed in Item 8.01 below), Synopsys, Inc. ("Synopsys") has suspended its financial guidance for the third quarter of fiscal year 2025 and full fiscal year 2025.

The information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. It shall also not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission by Synopsys whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

#### Item 8.01 Other Events.

On May 29, 2025, following the announcement of Synopsys' financial results of its second fiscal quarter ended April 30, 2025, Synopsys received a letter from the Bureau of Industry and Security of the U.S. Department of Commerce informing Synopsys of new export restrictions related to China (the "BIS Letter"). Synopsys is currently assessing the potential impact of the BIS Letter on its business, operating results and financial condition.

#### **Cautionary Statement Regarding Forward-Looking Statements**

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding Synopsys' assessment of the potential impact of the BIS Letter. These statements involve risks, uncertainties and other factors, including those factors listed in Synopsys' most recent reports on Form 10-K and Form 10-Q, that could cause our actual results, time frames or assessment to differ materially from those expressed or implied in such forward-looking statements. The information provided herein is as of May 29, 2025. Synopsys undertakes no duty to, and does not intend to, update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the	
undersigned, hereunto duly authorized.	

	SYNO	PSYS, INC.
Dated: May 29, 2025	Ву:	/s/ John. F. Runkel, Jr.
		John F. Runkel, Jr.
		General Counsel and Corporate Secretary